These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9113074)

  • 1. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
    Valgardsdottir R; Tryggvadottir L; Steinarsdottir M; Olafsdottir K; Jonasdottir S; Jonasson JG; Ogmundsdottir HM; Eyfjörd JE
    APMIS; 1997 Feb; 105(2):121-30. PubMed ID: 9113074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
    Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
    Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of TP53 alterations in breast carcinoma.
    Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
    Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
    Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
    Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
    Andersen TI; Børresen AL
    Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 abnormalities and genetic instability in breast cancer.
    Eyfjörd JE; Thorlacius S; Valgardsdottir R; Gretarsdottir S; Steinarsdottir M; Anamthawat-Jonsson K
    Acta Oncol; 1995; 34(5):663-7. PubMed ID: 7546836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.
    Langerød A; Zhao H; Borgan Ø; Nesland JM; Bukholm IR; Ikdahl T; Kåresen R; Børresen-Dale AL; Jeffrey SS
    Breast Cancer Res; 2007; 9(3):R30. PubMed ID: 17504517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 abnormalities and genomic instability in primary human breast carcinomas.
    Eyfjörd JE; Thorlacius S; Steinarsdottir M; Valgardsdottir R; Ogmundsdottir HM; Anamthawat-Jonsson K
    Cancer Res; 1995 Feb; 55(3):646-51. PubMed ID: 7530599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
    Helland A; Holm R; Kristensen G; Kaern J; Karlsen F; Trope C; Nesland JM; Børresen AL
    J Pathol; 1993 Oct; 171(2):105-14. PubMed ID: 8283348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer.
    Ozcelik H; Pinnaduwage D; Bull SB; Andrulis IL
    Breast Cancer Res Treat; 2007 Nov; 105(3):255-65. PubMed ID: 17221157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
    Skomedal H; Kristensen G; Helland A; Nesland JM; Kooi S; Børresen AL; Holm R
    Br J Cancer; 1995 Jul; 72(1):129-33. PubMed ID: 7599041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
    Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
    Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 alterations in atypical ductal hyperplasia and ductal carcinoma in situ of the breast.
    Chitemerere M; Andersen TI; Holm R; Karlsen F; Børresen AL; Nesland JM
    Breast Cancer Res Treat; 1996; 41(2):103-9. PubMed ID: 8944328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.
    Abdel-Fattah R; Challen C; Griffiths TR; Robinson MC; Neal DE; Lunec J
    Br J Cancer; 1998 Jun; 77(12):2230-8. PubMed ID: 9649138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance.
    Silwal-Pandit L; Vollan HK; Chin SF; Rueda OM; McKinney S; Osako T; Quigley DA; Kristensen VN; Aparicio S; Børresen-Dale AL; Caldas C; Langerød A
    Clin Cancer Res; 2014 Jul; 20(13):3569-80. PubMed ID: 24803582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.